To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
MDRNA, Inc. Announces Research Study With Pfizer
Read time: Less than a minute
MDRNA, Inc. has announced a study effort with Pfizer. The relationship will focus on the evaluation of MDRNA's proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi).
Additional details of the collaboration were not disclosed. This marks MDRNA's fourth early collaborative effort announced with a major pharmaceutical company in the past nine months.
MDRNA will be responsible for formulating Pfizer's oligonucleotides in DiLA2 formulations for in vivo preclinical evaluation to be performed at Pfizer. Additionally, MDRNA's research team will design and synthesize UsiRNAs directed against targets specified by Pfizer.
"We are extremely pleased to be working with Pfizer, a world leader in the pharmaceutical industry," said Michael French, President and CEO of MDRNA. "As Pfizer has made a commitment to the research and development of RNAi therapeutics, this is a significant opportunity for MDRNA to again demonstrate the broad capabilities of its world-class research team and proprietary drug discovery engine for RNAi-based therapeutics."
Additional details of the collaboration were not disclosed. This marks MDRNA's fourth early collaborative effort announced with a major pharmaceutical company in the past nine months.
MDRNA will be responsible for formulating Pfizer's oligonucleotides in DiLA2 formulations for in vivo preclinical evaluation to be performed at Pfizer. Additionally, MDRNA's research team will design and synthesize UsiRNAs directed against targets specified by Pfizer.
"We are extremely pleased to be working with Pfizer, a world leader in the pharmaceutical industry," said Michael French, President and CEO of MDRNA. "As Pfizer has made a commitment to the research and development of RNAi therapeutics, this is a significant opportunity for MDRNA to again demonstrate the broad capabilities of its world-class research team and proprietary drug discovery engine for RNAi-based therapeutics."
